Citations

Clear

30 citation(s) found for "SPIROMICS".

Unraveling the Role of Cell-free DNA as a Biomarker in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
Richert, Mary, Gao, Songqi, Keller, Michael , Bateman, Lori A. , Bleecker, Eugene R., Christenson, Stephanie A. , Meyers, Deborah A. , Ortega, Victor E. , Woodruff, Prescott G. , Curtis, J.L., Investigators, SPIROMICS, Christenson, Stephanie A , Kong, Hyesik , Jang, Moon Kyoo , Tian, Xin , Andargie, Temesgen Ewunetu , Bowler, Russell P. , O’Neal, Wanda K. , Martínez, Fernando J. , Curtis, J.L., Agbor-Enoh, Sean T.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3192-A3192

10.1164/ajrccm.2025.211.abstracts.a3192 Get It

Abstract Rationale: Individuals with chronic obstructive pulmonary disease (COPD) have different clinical trajectories, some with minimal symptom burden, others experiencing recurrent exacerbations, the most severe of which require hospitalization. Existing diagnostics, including spirometry and symptom assessments, lack the precision to identify high-risk patients who may benefit from timely preventive therapies. Nuclear cell-free DNA (ncfDNA) is a well-established marker of systemic tissue injury, implicated in amplifying inflammation by triggering type 1 interferon release by activating DNA-sensing pathways. Because COPD is accompanied by inflammation and tissue injury systemically, we hypothesized that ncfDNA is associated with increased risk of severe exacerbations requiring hospitalization. Methods: Design: We utilized baseline plasma samples randomly selected from 672 individuals with COPD from the Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) cohort, which prospectively collected exacerbation numbers and type. The primary endpoint was exacerbation requiring hospitalization. Secondary endpoints included total number of exacerbations (defined as use of oral steroids, antibiotics, or healthcare utilization) and severe exacerbations (defined as requiring emergency room care or hospitalization). Measure: We measured plasma ncfDNA using digital droplet PCR. Analysis: We assessed the association of ncfDNA with exacerbation outcomes using negative binomial regression or Cox regression, adjusting for age, percent post-bronchodilator forced expiratory volume in one second (FEV1), supplemental oxygen use, and smoking status. Results: In total, 57% (n=383) of COPD participants experienced exacerbations, 29% (n=197) at least one severe, and 22% (n=145) requiring hospitalization, the latter at a median of 622 days from enrollment (IQR=287-997). Higher ncfDNA levels at enrollment correlated with measures of COPD severity, including baseline FEV1 (beta = -0.12, 95% CI -0.18 to -0.049, p <0.001). Higher ncfDNA associated with increased risk of COPD exacerbation requiring hospitalization (incidence rate ratio (IRR) 1.40, 95% CI 1.12-1.75, p =0.003) and severe exacerbations (IRR 1.36, 95% CI 1.11-1.67, p=0.002) and a trend towards total exacerbations (IRR 1.11, 95% CI 0.98-1.26, p= 0.09). The primary outcome, risk of time-to-first hospitalization, correlated significantly with higher ncfDNA with hazard ratio (HR) 1.23, 95% CI 1.01-1.49, p=0.037. Conclusion: These results suggest that ncfDNA may serve as a predictor for severe and hospitalization-associated COPD exacerbations. To better understand the relationship between ncfDNA and COPD pathophysiology, follow-up studies should explore longitudinal trends and cfDNA tissue sources, and their link to COPD exacerbations.
Single Nucleotide Variants in the Fc Receptor for IgG Are Associated With COPD Severity and Exacerbations in African American Participants From COPDGene and SPIROMICS
LaFon, David C. , Hu, Kaili , Rocco, Alison, Ortega, V.E., Woodruff, P., Christenson, Stephanie A. , Martinez, F.J., Paine, Richard R. , Meyers, Deborah A. , Putcha, Nirupama , Curtis, J.L., Christenson, Stephanie A , Kaner, Robert J. , Krishnan, Jerry A , Curtis, J.L., Labaki, Wassim W. , Pandey, Janardan P. , Nahm, Moon H. , Chong, Zechen , McDonald, Merry‐Lynn

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3188-A3188

10.1164/ajrccm.2025.211.abstracts.a3188 Get It

Abstract Rationale: We have previously shown reduced total IgG, IgG subclasses, and levels/function of pneumococcal-specific antibodies are associated with increased risk for exacerbations of COPD (ECOPD). The binding of IgG to its receptor, the Fc receptor for IgG (FcγR) on immune cells, has a critical role in determining antibody levels and function. In addition to our research demonstrating that IgG heavy chain gene (IGHG) variants are associated with ECOPD, single nucleotide variants (SNVs) in genes encoding FcγR (FCGR1-3, which encode receptor subtypes FcγRI, FcγRIIa/b/c, and FcγRIIIa/b) may also result in antibody deficiency and increased exacerbation risk. Due to technical challenges in accurately identifying SNVs in FCGR, this region has not been well-characterized. The limited data that exist are from people of European descent, and prior studies have not included African American participants. We therefore sought to investigate the hypothesis that distinct SNVs in genes encoding FcγR are associated with disease severity and history of exacerbations in African American people with COPD. Methods: We developed a novel pipeline to identify SNVs in the coding (CDS) regions of chromosome 1 using short-read whole genome sequence data. The pipeline was benchmarked using paired long-read samples from Genome in a Bottle. SNVs were called within CDS regions and analyzed in a meta-analysis of self-reported African American participants in SPIROMICS and COPDGene (n=3063). Genetic variants were tested for association with COPD severity (GOLD spirometry stage 1-2 vs 3-4) as well as COPD exacerbations, adjusting for age, sex and principal components controlling for population structure. Results: Eight SNVs were significantly associated with frequent ECOPD (≥2 in one year) in the meta-analysis of African American COPDGene and SPIROMICS participants (Table). Seven of these 8 SNVs were found in FCGR3; 4 in the activating FCGR3A subtype, and 3 in FCGR3B. Seven of 11 SNVs associated with COPD severity were in FCGR3 (4 in FCGR3A; 3 in FCGR3B). One SNV (rs371849) was associated with both frequent exacerbations (P=0.002) and COPD severity (P=0.044). Conclusions: We used a cutting-edge variant calling pipeline to identify multiple SNVs in FCGR, primarily involving FcγRIII receptor subtypes, associated with COPD severity and exacerbations in African American participants in SPIROMICS and COPDGene. FcγRIII variants are known to cause impaired antibody levels and function in people of European descent. The structural and functional importance of newly recognized variants in African American cohorts require further study, as they may represent immunogenetic risk factors for antibody deficiency and exacerbations.
Gene Expression Deconvolution of Hair Follicle Cells Demonstrates Lung-Relevant Cell Types. The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
Buschur, Kristina L., Martorella, Molly , Garcia-Flores, Renee , Bleecker, Eugene R., Christenson, Stephanie A. , Criner, G.J., Dransfield, M.T., Hansel, Nadia N. , Meyers, Deborah A. , Oelsner, Elizabeth C. , Paine, Robert , Woodruff, Prescott G. , Oelsner, Elizabeth C , Christenson, Stephanie A , Smith, Benjamin M. , Ziosi, Marcello , Barjaktarević, Igor , Comellas, Alejandro P. , Criner, G.J., Kaner, Robert J. , Krishnan, Jerry A , Barr, R. Graham , Lappalainen, Tuuli

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2526-A2526

10.1164/ajrccm.2025.211.abstracts.a2526 Get It

Abstract Rationale. Bronchoscopy can directly assess cells in airway epithelium in participants with COPD, but it is invasive, expensive, difficult to perform at scale, and contraindicated in severe disease. Blood is much more easily available but contains only a limited subset of cell types, many of which are less relevant to lung biology. Recent advances in RNA-sequencing technology have allowed for reliable measurement of transcriptomics in a wider variety of more accessible tissues, including hair follicle cells. We collected and performed bulk RNA-seq on hair follicles as an ancillary study within the NIH-funded SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) and investigated their cell type composition to better understand the opportunities and limitations of this tissue for the study of lung disease. Methods. SPIROMICS recruited individuals with and without COPD aged 40-80 years with ≥ 20 pack-years smoking history. Participant at several sites underwent collection of approximately 10 hair follicles from the head, which were immediately frozen at -80ºC in 2018-21. mRNA in hair follicles was measured by bulk RNA-seq, and cell type deconvolution was performed using GEDIT v1.7 with the provided BlueCodeV1.0.tsv reference matrix. Cell types were collapsed into broader categories by summing the estimated cell type proportions. Results. The cell type deconvolution of the hair follicle bulk RNA-seq from 80 participants with and without COPD estimated that the tissue was largely composed of immune cells (median 36%, including B cells, T cells, neutrophils, macrophages, NK cells, and monocytes) and epithelial cell types (median 31%), with the largest subgroup of epithelial cell types identified as hair follicular keratinocytes (Figure 1). The next largest component was fibroblasts (median 9%), followed by endothelial cells (median 8%). Signals for myocytes (median 5%), melanocytes (median 5%), and chondrocytes (median 5%) were also present. Conclusion. This initial study demonstrated promising signals for a variety of lung-relevant cell types in hair follicles in SPIROMICS, including immune and epithelial cells in addition to fibroblasts and endothelial cells that are not otherwise easily accessible. Hair follicle gene expression profiling shows promise for understanding numerous facets of lung biology and disease that both complements and exceeds that of other noninvasive tissues such as blood.
Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin–Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort
Barjaktarević, Igor , Hixson, Roxana, Zhuang, Zian , Buhr, Russell G. , Tejwani, Vickram , Barr, R. Graham, Bateman, Lori A. , Bhatt, Surya P. , Bleecker, Eugene R. , Cooper, Christopher B., Fortis, Spyridon , Hansel, Nadia N. , Hoffman, Eric A. , Martinez, Fernando J., Meyers, Deborah A., Paine, Robert, Pirozzi, C.S. , Sandhaus, Robert A. , Tashkin, Donald P., Wells, J. Michael , Woodruff, Prescott G. , Ortega, Victor E. , Drummond, M Bradley , Fortis, Spyridon , Hoffman, Eric A , Wells, J Michael , Barjaktarevic, Igor , Buhr, Russell G , Bhatt, Surya P , Barr, R. Graham, Curtis, Jeffrey L. , Drummond, Michael , Ghosh, Auyon , Han, MeiLan King , Ohar, Jill , Meyers, Deborah A. , Strange, Charlie

Mayo Clinic

Annals of the American Thoracic Society | March 11, 2025 | Volume: 22 | Issue: 7 | Pages: 998-1008

10.1513/annalsats.202411-1209oc | PMID 40068143 Get It

Abstract Rationale Reliable data about the natural history of lung function decline in alpha-1 antitrypsin (AAT)-deficient Pi*MZ heterozygotes is largely missing. Objectives We hypothesized that, in adults with a tobacco smoking history, lung function deteriorates faster in Pi*MZ compared with the Pi*MM genotype. Methods We identified 1,856 Pi*MM and 79 Pi*MZ participants with ⩾20 pack-years tobacco smoking history from the SPIROMICS (Subpopulations and Intermediate Outcomes Measures in COPD Study) cohort by DNA sequencing and followed them over a median of 4.8 years, comparing radiographic and clinical characteristics between the two groups over time using regression models. Results Adjusted for age, sex, race, smoking pack-year history, and smoking status, Pi*MZ participants had a lower baseline percent predicted forced expiratory volume in 1 second (FEV1) (65.4% vs. 75.1%; difference 95% confidence interval [CI], −15.4% to −3.9%), more radiographic emphysema (<−950 Hounsfield units%, 12.9% vs. 7.8%; difference 95% CI, 2.8% to 7.5%), and nonsignificantly lower lung density. In the longitudinal analysis, the FEV1 annual rate of decline was similar in both groups over the course of the study (−34.5 ml/yr vs. −34.6 ml/yr for Pi*MZ and Pi*MM; difference 95% CI, −16.9 to 17.1 ml/yr). There were no significant differences between Pi*MZ and Pi*MM individuals in the annualized change in lung density, emphysema, patient-reported outcomes, exacerbations, or survival. The proportion with faster FEV1 decline (annual loss ⩾40 ml) was similar in Pi*MZ and Pi*MM groups. In both groups, faster FEV1 decline was associated with more air trapping and small airway disease at baseline. In Pi*MZ only, faster decline was associated with higher blood eosinophil counts (310 vs. 220 cells/μl; difference 95% CI, 30 to 140 cells/μl). In the subgroup analysis limited to a small number of currently smoking participants, no significant differences in longitudinal outcomes were found. Conclusions Despite a lower FEV1 and more emphysema at enrollment, the longitudinal analysis did not demonstrate significantly greater lung function decline or lung density loss in Pi*MZ compared with Pi*MM participants with tobacco smoking history. Limited sample size and duration of longitudinal follow-up constrain generalizability of our findings, thus prohibiting the conclusion that longitudinal trajectories did not differ between these groups. However, our results may suggest that earlier life events could be responsible for more extensive lung disease at enrollment in Pi*MZ compared with Pi*MM tobacco-exposed individuals.
Clinical Characteristics and Longitudinal Outcomes in Heterogeneous Emphysema in SPIROMICS
Hong, Angela , Newell, John D. , Valipour, Arschang , Ortega, Victor E. , Cooper, C.B., Hansel, Nadia N. , Paine, Robert , Woodruff, P., Hong, A., Eddy, Rachel L. , Goldin, Jonathan , Hoffman, Eric A. , Abtin, Fereidoun G. , Criner, Gerard J. , Reinhardt, Joseph M. , Barr, R. Graham , Ohar, Jill , Curtis, Jeffrey L. , Cooper, C.B. , Drummond, Michael , Han, MeiLan King , Labaki, Wassim W. , Martínez, Fernando J. , Wells, J. Michael , Tashkin, Donald P. , Barjaktarević, Igor

Mayo Clinic

D13. DETERMINANTS OF DISEASE PROGRESSION AND DECLINE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6905-A6905

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6905 Get It

Longitudinal Progression of CT Emphysema Subtypes Using Density-based and Hidden Markov Measure Field-based Thresholds: The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
Wysoczanski, Artur , Bowler, R.P., Cooper, Christopher B. , Menchaca, Martha , Ortega, Victor E. , Paine, Robert , Woodruff, Prescott G. , Laine, Andrew F. , Angelini, Elsa D. , Hermann, E.A. , Dransfield, Mark T. , Han, MeiLan King , Hoffman, Eric A. , Krishnan, Jerry A , Menchaca, M.G., Ohar, Jill , Smith, Benjamin M. , Sun, Yuan‐Wan , Barr, R. Graham

Mayo Clinic

D15. MACHINE LEARNING AND LARGE COHORT STUDIES TO UNDERSTAND EXPOSURE-RELATED LUNG DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6928-A6928

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6928 Get It

Computer Assisted Quantitative Image Analysis as a Pathway to Identification of Combined Pulmonary Fibrosis and Emphysema (CPFE): Analysis of the SPIROMICS Cohort
HOESTEREY, DANIEL , Kim, G.H.J., Lee, Jungmin , Pourzand, Lila , Oh, Andrea , Bateman, Lori A. , Cooper, C.B., Hansel, Nadia N. , Kim, V., Ortega, Victor E. , Paine, Robert , Peters, Stephen P. , Wang, J.M., Woodruff, Prescott G. , Abtin, F., Tashkin, Donald P. , Hoffman, Eric A. , Barr, R. Graham , Bowler, Russell P. , Cooper, C.B. , Couper, David , Curtis, Jeffrey L. , Dransfield, Mark T. , Drummond, Michael , Han, MeiLan King , Kaner, Robert J. , Krishnan, Jerry A , Martínez, Fernando J. , Reinhardt, Joseph M. , Wells, J. Michael , Goldin, Jonathan , Abtin, Fereidoun G. , Barjaktarević, Igor

Mayo Clinic

C24. CLINICAL, BIOLOGIC, AND RADIOLOGIC MARKERS OF KEY OUTCOMES AND TREATMENT RESPONSE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5118-A5118

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5118 Get It